Kallikrein-3 (KLK3), widely known as Prostate-Specific Antigen (PSA), is a 33-kDa serine protease predominantly secreted by the prostatic epithelium. While historically utilized as the gold-standard diagnostic biomarker for prostate cancer, KLK3 is increasingly targeted as a functional therapeutic node. Modern drug discovery strategies leverage KLK3's localized enzymatic activity for prostate-specific prodrug activation, or target its peptides for therapeutic vaccines and adoptive cellular therapies (TCR-T/CAR-T). Maintaining a strict distinction from membrane-bound targets like PSMA (FOLH1), KLK3 drug development requires highly specific reagents that account for its secreted nature, enzymatic state (zymogen vs. active protease), and high sequence homology within the kallikrein family.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLK3/PSA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLK3/PSA Recombinant Protein (Active/Inactive forms) High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed for native glycosylation. Sequence Verified. |
View KLK3 Products |
| Gene Delivery | KLK3/PSA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and antigen expression validation. |
View KLK3 Products |
| Benchmark Ab | Anti-KLK3/PSA Antibody Recombinant positive control antibody for assay development and specificity validation. |
View KLK3 Products |
| Validator | KLK3/PSA siRNA Set For target knockdown verification in prostate cancer cell lines. |
View KLK3 Products |
| Related Target A | KLK2 (Kallikrein-2) Shares ~80% sequence homology with KLK3. Essential for counter-screening to ensure off-target safety. |
View KLK2 Products |
| Related Target B | AR (Androgen Receptor) Upstream transcriptional regulator of KLK3 expression. Crucial for correlation assays in hormone-sensitive models. |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity with homologous Kallikreins | Recombinant KLK2 and other family members available (>95% purity) for rigorous counter-screening panels. |
| Enzymatic activity verification | HEK293-expressed active serine protease forms with verified theoretical molecular weight and intact catalytic triads. |
| Lack of Controls | Clinical benchmark recombinant antibodies included to establish baseline assay sensitivity. |
| False Positives in Knockdown | Sequence-verified siRNA pools included for target-specific transcriptional silencing. |
Live KLK3/PSA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of KLK3/PSA is undergoing a renaissance. Moving beyond its role as a serum biomarker, drug developers are capitalizing on the high local concentrations of active KLK3 in the prostate tumor microenvironment. The dominant therapeutic modalities include PSA-activated peptide-drug conjugates (prodrugs), peptide-based therapeutic vaccines (e.g., PROSTVAC), and TCR-T cell therapies targeting HLA-presented PSA peptides. As clinical trials advance, the key technical hurdle remains the identification of agents that selectively interact with tumor-associated KLK3 without being neutralized or sequestered by systemic protease inhibitors like alpha-1-antichymotrypsin (ACT) in circulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PSA-Activated Prodrugs | Merck, Academic Institutions | mCRPC (Metastatic Castration-Resistant Prostate Cancer) | Active protease cleavage assays requiring stable, glycosylation-verified active KLK3 protein. |
| Therapeutic Vaccines | Bavarian Nordic, National Cancer Institute | Localized & Metastatic Prostate Cancer | Antigen presentation assays requiring high-purity, low-endotoxin full-length KLK3. |
| Adoptive Cell Therapy (TCR-T) | Biotech Startups, Clinical Consortia | Advanced Prostate Malignancies | HLA-peptide binding stability and specificity screens using sequence-verified target proteins. |